Understanding Fortress Biotech
Source: Daniel Carlson for Streetwise Reports  (2/5/20)
Daniel Carlson of Tailwinds Research takes a close look at what he calls a "great value opportunity," with a focus on subsidiary Avenue Therapeutics. More >

Insmed Shares Trade 40% Higher on Phase 2 Top-Line Bronchiectasis Trial Data
Source: Streetwise Reports  (2/3/20)
Insmed Inc.'s shares traded higher today after the company reported positive top-line results from its Phase 2 WILLOW Study of INS1007 in patients with non-cystic fibrosis bronchiectasis. More >

'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'
Source: Streetwise Reports  (1/31/20)
The compelling aspects of this life sciences story are presented in a Dawson James report. More >

Syndax Pharma Shares Rise on $35M Capital Raise, Credit Line and Positive Phase 1/2 Leukemia Trial Results
Source: Streetwise Reports  (1/31/20)
Syndax Pharmaceuticals' shares traded 30% higher after the company reported it expects to raise $35 million from a common stock offering from five institutional investors and secured a $30 million non-dilutive term loan facility. More >

CEO Reviews Life Sciences Firm's Year of 'Exceptional Accomplishment'
Source: Streetwise Reports  (1/30/20)
The company makes progress getting its products approved and sold in more countries. More >

Arcadia Ropes in $3 Million in GoodHemp Seed Purchase Orders Within 50 Days of Product Launch
Source: Streetwise Reports  (1/30/20)
Arcadia Biosciences shares traded 25% higher after reporting that it secured $3 million in pre-season GoodHemp seed purchase commitments in just 50 days after launching the product. More >

Two Approvals Underscore Biotech's Pipeline Quality
Source: Streetwise Reports  (1/29/20)
The green lights and their implications are discussed in an H.C. Wainwright & Co. report. More >

California Gold: Two U.S. Hemp Revenue Streams Coming Online This Quarter
Source: Peter Epstein for Streetwise Reports  (1/29/20)
Peter Epstein of Epstein Research discusses recent developments at the company. More >

Acceleron Shares Open 50% Higher on Phase 2 PAH Trial Data
Source: Streetwise Reports  (1/28/20)
Acceleron Pharma's shares established a new 52-week high after the company reported that sotatercept achieved both primary and secondary endpoints in the Phase 2 PULSAR study in patients with pulmonary arterial hypertension. More >

Inovio Pharma Awarded $9M Development Grant for Coronavirus Vaccine
Source: Streetwise Reports  (1/27/20)
Inovio Pharmaceuticals' shares rose 30%, setting a new 52-week high price, after the firm reported it received a grant of up to $9 million to develop a vaccine against the coronavirus. More >

My Prediction for a Market Top in October Was Perhaps Left but Not Wrong
Source: Bob Moriarty for Streetwise Reports  (1/26/20)
Bob Moriarty of 321gold reflects on how government actions in the financial and public health spheres will pop market bubbles. More >

Neurotrope's Shares Double on Phase 2 Alzheimer's Study Data and $2.7 Million NIH Grant
Source: Streetwise Reports  (1/22/20)
Neurotrope's shares traded higher today after reporting results from its Phase 2 "203" clinical trial of Byrostatin-1 for treatment of moderately severe to severe Alzheimer's patients. The firm has also been awarded a $2.7 million grant from the National Institutes of Health to conduct additional clinical research for patients with advanced Alzheimer's disease. More >

Biopharma Shows 'Good Start to 2020 News Flow'
Source: Streetwise Reports  (1/21/20)
The two developments that already took place this year are addressed in an H.C. Wainwright & Co. report. More >

Genprex Shares Soar 250% on FDA Fast Track Designation for Lung Cancer Drug
Source: Streetwise Reports  (1/21/20)
Genprex's shares spiked 380% higher in morning trading as the company reported that the FDA granted Fast Track Designation for its Oncoprex immunogene therapy in combination with EGFR inhibitor osimertinib. More >

InMed Shares Trade Up 25% After Becoming First to Advance Cannabinol into Clinical Trials
Source: Streetwise Reports  (1/20/20)
InMed Pharmaceuticals shares traded 25% higher after reporting that it is the first to advance cannabinol into therapeutic clinical trials. More >

NantKwest Shares Jump More than 50% Following JP Morgan Healthcare Conference Presentation
Source: Streetwise Reports  (1/16/20)
Shares of NantKwest Inc. spiked as much as 85% higher in mid-morning trading setting a new 52-week high price after the company reported a series of positive results at the 38th J.P. Morgan Healthcare Conference in San Francisco. The firm reported that complete responses were noted in as many as six different multiple tumor types when "natural killer" cells and T cells are activated simultaneously. More >

Biotech Announces Deal with Bayer on Non-Hormonal Contraception
Source: Streetwise Reports  (1/15/20)
Details of the arrangement and an update on the company's pipeline are provided in a Dawson James report. More >

Adaptimmune Shares Triple as SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
Source: Streetwise Reports  (1/13/20)
Shares of Adaptimmune Therapeutics more than tripled in value after the company reported that its SPEAR T-cell platform delivered positive initial responses in four different solid tumor indications. More >

Life Sciences Firm Upgrades to OTCQB Venture Market
Source: Streetwise Reports  (1/10/20)
This is a significant achievement of this developing company. More >

Ultragenyx Shares Increase 30% on Results from Phase 1/2 OTC Deficiency Study
Source: Streetwise Reports  (1/10/20)
Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency. More >

Applied Genetic Tech's Shares Double on 6-Month X-Linked RP Study Results
Source: Streetwise Reports  (1/9/20)
Shares of Applied Genetic Technologies skyrocketed to a new 52-week high price after the company reported positive six-month data from its ongoing Phase 1/2 clinical study for treatment in X-Linked Retinitis Pigmentosa. The firm stated that the trial data suggests durable and meaningful improvements in central visual sensitivity and advised that it plans to initiate a pivotal trial by year-end 2020. More >

Developer of Oncology Therapeutics to Have 'Catalyst Rich' 2020
Source: Streetwise Reports  (1/8/20)
The near-term events expected to trigger movement of the biotech's share price are outlined in a ROTH Capital Partners report. More >

Applied Therapeutics Investors Like the ACTION in Phase 2 Galactosemia Study
Source: Streetwise Reports  (1/8/20)
Applied Therapeutics' shares traded 25% higher today after the company reported positive topline results from its Pivotal Phase 2 ACTION Study of AT-007 for use in the treatment of galactosemia. The firm expects to file for regulatory approval of AT-007 in H2/20. More >

Apellis Pharma Shares Rise 20% on Positive Top-line Data in Phase 3 PNH Trial
Source: Streetwise Reports  (1/7/20)
Shares of Apellis Pharmaceuticals opened 35% higher and established a new 52-week intraday high price today after the company announced positive top-line results from its Phase 3 head-to-head study of Pegcetacoplan (APL-2) versus Eculizumab in patients with Paroxysmal Nocturnal Hemoglobinuria. More >

Kyorin's $175M Partnership Offers Good Life for aTyr Pharma in Japan
Source: Streetwise Reports  (1/6/20)
aTyr Pharma's shares traded 45% higher today after the firm reported that it had entered into a collaboration agreement with Kyorin Pharmaceutical for development and commercialization of its ATYR1923 drug in Japan. More >